Combination chemotherapy with methotrexate and vinblastine for surgically unresectable, aggressive desmoid tumor

Combination chemotherapy with methotrexate and vinblastine for surgically unresectable, aggressive desmoid tumor - Chemotherapy for desmoid

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030998

Enrollment

Registered

2018-01-25

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

desmoid tumor

Interventions

A doseof 30 mg/m 2of methotrexate and 5 mg/m of vinblastine was administered weekly by intravenous infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: pathological diagnosed with desmoid Progressive disease with previous treatment 16 years old or more and 85 or less Neu over 1,000/mm3 Plt over 75,000/mm3 Hb over 8.0g/dl AST(GOT)ALT(GPT)150U/L or less T-bli : 3 or less CCr: 30 or more ECOG Performance Status 0 to 2 Informed Consent is obtained

Exclusion criteria

Exclusion criteria: contraindication for methotrexate or vinblastine, severe heart disease, renal dyfunction, respiratory failure, caogulation disorder pregnant Other medical, social, or psychological conditions that in the opinion of an investigator precludes the patient from appropriate consent

Design outcomes

Primary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactKatsuhiro Hayashi

Kanazawa University Hospital Orthopaedic department

khayashi830@gmail.com0762652374

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026